Dergiler / Journal of Experimental and Clinical Medicine / 2016 / Cilt: 33 - Sayı: 2

MCP-1-2518 A>G and CCR2 V64I polymorphisms in Turkish patients with lung cancer

Sayfa
79–84
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Our findings suggest that MCP1 -2518 A>G and CCR2 V64I polymorphisms are not associated with genetic susceptibility to lung cancer and lung cancer metastasis.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:In the current study, we aimed to investigate the possible role of MCP-1 -2518 A>G and CC chemokine receptor 2 (CCR2) V64I polymorphisms in patients with lung cancer.
📊
Temel Bulgular & Veri:Sixty-five patients with lung cancer (57 with NSCLC and 8 with SCLC) and 57 healthy controls were enrolled.
💡
Sonuç & Katkı:Our findings suggest that MCP1 -2518 A>G and CCR2 V64I polymorphisms are not associated with genetic susceptibility to lung cancer and lung cancer metastasis.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

In the current study, we aimed to investigate the possible role of MCP-1 -2518 A>G and CC chemokine receptor 2 (CCR2) V64I polymorphisms in patients with lung cancer. Sixty-five patients with lung cancer (57 with NSCLC and 8 with SCLC) and 57 healthy controls were enrolled. Polymerase chain reactionrestriction fragment length polymorphism (PCR-RFLP) method was used. Genotype distribution of monocyte chemoattractant protein 1 (MCP-1) -2518 A>G polymorphism in lung cancer patients was as follows: 30 for AA, 30 for AG and 5 for GG genotype. Frequency of minor G allele in patients and controls were found as 30.8% and 23.7%, respectively. In patients, genotype distribution of CCR2 V64I polymorphism was as follows: 47 for GG, 16 for GA, and 2 for AA. Frequency of minor A allele was found in patients and controls as 15.4% and 19.2%, respectively. Genotype distribution and allele frequencies of MCP-1 and CCR2 polymorphism were not statistically different between patients and controls (p values >0.05 for both polymorphisms). In lung cancer patients, there was no significant association between smoking status and MCP-1 and CCR2 polymorphisms. Similarly, no significant association was found between distant organ metastasis and both gene polymorphisms. Our findings suggest that MCP1 -2518 A>G and CCR2 V64I polymorphisms are not associated with genetic susceptibility to lung cancer and lung cancer metastasis.

🔖

Bu Makaleye Atıf Yap

KUCUK, H. K., ARSLAN, S., YİLDİRİM, M. E., SEZGİN, I., BAGCİ, B., BAGCİ, G. (2022). MCP-1-2518 A>G and CCR2 V64I polymorphisms in Turkish patients with lung cancer. Journal of Experimental and Clinical Medicine, Cilt: 33 - Sayı: 2, 79–84. https://ajindex.com/articles/563037

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (5)

  1. Arslan, S., Dogan, T., Koksal, B., Yildirim, M.E., Gumus, C., Elagoz, S., Akkurt, I., Ozdemir, O., 2008. Tumoral tissue specific promoter hypermethylation of distinct tumor suppressor genes in a case with nonsmall cell lung carcinoma: A case report. Lung India. 25, 148-151. doi:10.4103/0970-2113.45279. Bagci, B., Bagci, G., Candan, F., Ozdemir, O., Sezgin, I., 2015. The protective effect of MCP-1-2518 A> G promoter polymorphism in Turkish chronic renal failure patients requiring long-term hemodialysis. Int. Urol. Nephrol. 47, 551-556. doi:10.1007/ s11255-015-0922-3.
  2. Balkwill, F., 2003. Chemokine biology in cancer. Semin. Immunol. 5, 49-55. doi:10.1016/S1044-5323(02)00127-6.
  3. Bektas-Kayhan, K., Unur, M., Boy-Metin, Z., Cakmakoglu, B., 2012. MCP-1 and CCR2 gene variants in oral squamous cell carcinoma. Oral Dis. 18, 55-59. doi:10.1111/j.1601-0825.2011.01843.x. Cai, Z., Chen, Q., Chen, J., Lu, Y., Xiao, X., Wu, Z., Zhou, Q., Zhang, J., 2009. Monocyte chemotactic protein 1 promotes lung cancer-induced bone resorptive lesions in vitro. Neoplasia. 11, 228-236. doi:10.1593/neo.81282. Charo, I.F., Taubman, M.B., 2004. Chemokines in the pathogenesis of vascular disease. Circ. Res. 95, 858-866. doi: 10.1161/01. RES.0000146672.10582.17. Cruz, C.S.D., Tanoue, L.T., Matthay, R.A., 2011. Lung cancer: Epidemiology, etiology, and prevention. Clin. Chest. Med. 32, 605- 644. doi:10.1016/j.ccm.2011.09.001. Decramer, M,. Janssens, W., Miravitlles, M., 2012. Chronic obstructive pulmonary disease. Lancet. 379, 1341-1351. doi:10.1016/ S0140-6736(11)60968-9.
  4. D'hulst, A.I., Vermaelen, K.Y., Brusselle, G.G., Joos, G.F., Pauwels, R.A., 2005. Time course of cigarette smoke-induced pulmonary inflammation in mice. Eur. Respir. J. 26: 204-213. doi:10.1183/09031936.05.00095204. Fenoglio, C., Galimberti, D., Lovati, C., Guidi, I., Gatti, A., Fogliarino, S., Tiriticco, M., Mariani, C., Forloni, G., Pettenati, C., Baron, P., Conti, G., Bresolin, N., Scarpini, E., 2004. MCP-1 in Alzheimer's disease patients: A-2518G polymorphism and serum levels. Neurobiol. Aging. 25, 1169-1173. doi:10.1016/j.neurobiolaging.2003.11.008. Hamilton, G., Rath, B., 2015. Smoking, inflammation and small cell lung cancer: Recent developments. Wien. Med. Wochenschr. 165, 379-386. doi:10.1007/s10354-015-0381-6.
  5. Kakinuma, T., Hwang, S.T., 2006. Chemokines, chemokine receptors, and cancer metastasis. J. Leukoc. Biol. 79, 639-651. doi:10.1189/jlb.1105633. Katrancioglu, N., Manduz, S., Karahan, O., Yilmaz, M.B., Sezgin, I